NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Q32 Bio Inc. QTTB
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$53.7M
EPS · FY25
$2.42
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
125.1%
Net margin · FY25
55.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 53.7M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
55 cents of every revenue dollar became profit this year.
Per share
USD 2.42
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
125.1%
Return on equity, FY2025
ROE
Operating margin31.5%
Net margin55.5%
Return on assets38.7%
Each USD of equity produced 125 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+81.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+155.9%
+81.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 61.8M
total assets, end of FY2025
Total assetsUSD 61.8M
EquityUSD 42.0M
CashUSD 48.3M
Current ratio4.85×
Equity funds 68% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.1
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
0.0
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
0.0
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
−0.0
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
2.42
−6.58
−153.96
−0.09
−1.73
−2.80
−2.47
−1.95
−12.10
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
125.1
·
·
−25.7
−52.4
−56.6
−45.7
−70.8
·
Shares out B
0.01
0.01
0.00
0.06
0.06
0.05
0.05
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed